Saturday, May 18th, 2013

Anne Altmeyer, Executive Director, Business Development & Licensing, Oncology, at Novartis as a Panelist at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

Anne Altmeyer, Executive Director, Business Development & Licensing, Oncology, at Novartis is a Panelist in “Panel Discussion: Innovative Partnering & Licensing Strategies” at the Oncology Partnering and Deal-making Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC. Panel Discussion: Innovative Partnering & Licensing Strategies Topics to be covered: • What [...]

Posted by GTCbio on Friday, December 30, 2011 at 11:27 pm
Filed under Technology · Tagged 88kDa autocrine, ADC, Adcetris, angiogenesis, Antibody Drug Conjugates, bevacizumab, bite, BiTE antibodies, blinatumomab, BRAF Risk assessment, BRAFV600E, Cancer, Cancer Drug Combinations, cancer drugs, Cancer Targets, Cancer Therapy, carcinoma, CD105, CD19/CD3, companion diagnostics, computerized tomography (CT), endoglin, Epigenetic Enzyme, EZH2, GP88, lung cancer, lymphoblastic leukemia, Lymphoma, Metastatic Melanoma, Monoclonal Antibody, non-Hodgkin’s lymphoma (NHL), NSCLC, oncology, Oncology Deal-making, Oncology Partnering, T lymphocytes, TRC105, VEGF, vemurafenib, ZelborafTM

Page 1 of 11

Press About

Anne Altmeyer, Executive Director, Business Development & Licensing, Oncology, at Novartis as a Panelist at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

Categories

Archives

Blogroll

Most Commented

Recent Comments

Footer #3 Widget

Search